MAP3K1 and breast carcinoma: Furthermore, in the TCGA breast cancer dataset, tumors with simultaneous loss of MAP3K1 or MAP2K4, its putative downstream effector, and PIK3CA alterations did not demonstrate enhanced transcriptional readouts (PIK3CA-GS, see ref. 20) of PI3K pathway activation (Supplementary Fig. 5).